AKT1 and metabolic syndrome: The level of miRNA-370-3p (Ramzan et al., 2020), miRNA-374b-5p (Masi et al., 2021), miRNA-23a-3p (Lozano-Bartolomé et al., 2017), miR-221 (Huang et al., 2021), and miRNA-26b (Xu et al., 2015) can affect Akt activity and improve MetS through key targets of lipid metabolism.